foxo4-dri senolytic 2024 study

foxo4-dri senolytic 2024 study The disordered p53 transactivation domain is the target of FOXO4 and the compound foxo4-dri peptide senolytic mouse study

Name: foxo4-dri senolytic 2024 study The disordered p53 transactivation domain is the target of FOXO4 and the compound foxo4-dri peptide senolytic mouse study
Brand: composequickly.com
SKU: 1606287513
Price: 28.74 USD
Availability: InStock
Rating: 4.2016 (5 reviews)

foxo4 dri peptide senolytic mouse study 2023 2024 Molecular modelling of the FOXO4 TP53 interaction to design peptides for the elimination of senescent cancer cells FOXO4 DRI Peptide for Cellular FOXO4 DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53 serine 15 phosphorylation Communications Biology FOXO4 DRI regulates endothelial cell senescence via the P53 signaling pathway PMC Frontiers Senolytic Peptide FOXO4 DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes

SKU: 1606287513 · From composequickly.com

4.2

USD28.74 USD77.74

Pay in 4 interest-free payments of $7.18 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 1 - Aug 6

Description

Leukemia 30:399408 de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC et al (2011) Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors